<DOC>
	<DOCNO>NCT02318693</DOCNO>
	<brief_summary>This study efficacy sitagliptin glibenclamide short-term treatment glucose variability use continuous glucose monitoring ( CGM ) Japanese participant type 2 diabetes mellitus ( T2DM ) . The primary hypothesis treatment sitagliptin superior treatment glibenclamide change baseline mean amplitude glycemic excursion ( MAGE ) continuous glucose monitoring ( CGM ) 13 day treatment .</brief_summary>
	<brief_title>Efficacy Sitagliptin Glibenclamide Glucose Variability Japanese Participants With Type 2 Diabetes Mellitus ( MK-0431-355 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Japanese participant diagnosis Type 2 diabetes mellitus History Type 1 diabetes mellitus ketoacidosis History insulin thiazolidinedione ( include fixeddose drug combination contain one drug ) 12 week study participation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>